The Large Volume Wearable Injectors Market size in Europe is anticipated to showcase a healthy CAGR from 2022 to 2027.
Injectors Large volume portable devices, too Called bolus injectors or non-insulin patch pumps, are medication delivery devices with a capacity greater than 1 ml of injectable volume. These devices can provide a variety of benefits to patients, such as making the administration more convenient and reducing patient suffering. Portable injectors are rapidly gaining importance in the European market due to their ability to deliver a high volume of viscous formulations. The administration of pharmaceuticals by intravenous (IV) infusion is expensive in health facilities. Self-administration of subcutaneous injections is expected to save 40% to 75% of costs.
Besides, administration by conventional methods presents risks such as inaccurate dosages and needle stick injuries. Chronic diseases such as diabetes, cardiovascular disorders, neurological disorders, autoimmune diseases, and various types of cancer are the leading causes of death and disability worldwide. The clinical conditions associated with these diseases affect the general quality of life of patients. Indeed, according to the World Health Organization (WHO), it is currently estimated that more than 37% of the European population suffers from at least one chronic disease.
The growth of the European market is mainly driven by factors such as the elevating generality of chronic diseases, technological developments and design development, and the limitations of the conventional drug delivery system. Specifically, large volume portable injectors used for subcutaneous drug delivery have become a preferred option for drug delivery in the home care setting. The distinction of these portable devices is designed to deliver highly viscous drugs (such as biologics) in more significant volumes (more generous than 1ml), contributing multiple dosing options (basal, bolus, or continuous), built-in safety mechanisms, and almost negligible risk of needle stick injuries. Such devices have aroused the interest of various players in this industry and are used to deliver both insulin and non-insulin drugs.
Today, the field is witnessing many innovations, such as the development of integrated mobile applications with intelligent health monitoring, artificial intelligence algorithms, and other exciting features (including provisions for reminders and the ability to connect to web-based portals to share medical data with interested healthcare providers), visual/audio confirmation notifications of medication administration, automatic medication reconstitution and alerts error. We believe that these efforts will likely stimulate the growth of the European market in the years to come.
However, the market is likely to have a negative impact due to the limitations of the conventional drug delivery system.
This research report on the European Large Volume Wearable Injectors Market has been segmented and sub-segmented into the following categories:
By Wearable Injector Type:
By Therapeutic Area:
By Mechanism of Injection:
Geographically, factors that are fuelling the growth of the European market are enhanced product efficacy in long term dosage, and predominantly the rising number of patients with long-term chronic disorders. The local authorities' heavy reimbursements in this region pave the way for large investments in Research and Developments.
Promising companies leading the European large volume wearable injectors market profiled in this report are Ypsomed AG, West Pharmaceutical Services Inc., Sensile Medical AG, Becton Dickinson and Company, Amgen Inc., Enable Injections Inc., Unilife Corporation, and Insulet Corporation.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com